英: androgen ablation therapy

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 女性におけるアンドロゲン欠乏症および治療の概要overview of androgen deficiency and therapy in women [show details]
… effects – Most androgens are aromatized to estrogens; thus, risks of estrogen therapy, including endometrial hyperplasia, are also possible with androgen treatment. Some women on testosterone develop abnormal …
2. 閉経後のアンドロゲン過剰症の評価およびマネージメントevaluation and management of postmenopausal hyperandrogenism [show details]
… For androgen-secreting ovarian tumors, bilateral salpingo-oophorectomy (BSO) is the treatment of choice , with or without hysterectomy as indicated. We suggest surgical resection of androgen-secreting …
3. 女性の性機能障害：マネージメントoverview of sexual dysfunction in women management [show details]
… estrogen therapy are also possible with androgen treatment. A possible association between testosterone administration and breast cancer risk has been reported . Also, some women on testosterone develop …
4. 性腺機能低下を呈する男性に対するテストステロン治療testosterone treatment of male hypogonadism [show details]
… to testosterone therapy should be evaluated before initiating testosterone treatment: Prostate cancer – A man who has a history of prostate cancer should generally not be treated with testosterone. A possible …
5. アンドロゲン受容体障害の診断および治療diagnosis and treatment of disorders of the androgen receptor [show details]
…long-term, high-dose androgen therapy given to overcome androgen resistance has not been systematically assessed. One prepubertal boy with PAIS was administered high doses of testosterone, resulting in greater …

Japanese Journal

ジャーナルクラブの広場がん進行性前立腺がんにおける経口レルゴリクスによるアンドロゲン除去療法

月刊薬事 = The pharmaceuticals monthly 62(16), 3218-3220, 2020-12
NAID 40022429008

転移性ホルモン感受性前立腺癌に対するアンドロゲン除去療法とアビラテロン酢酸エステル+低用量プレドニゾロン療法の当院での初期治療経験 : 複合アンドロゲン遮断療法との有効性と安全性の比較検討

安川瞳,池端良紀,坪井康真,西山直隆,渡部明彦,藤内靖喜,北村寛
泌尿器科紀要 = Acta urologica Japonica 66(12), 427-432, 2020-12
Abiraterone acetate plus prednisone/prednisolone (AAP) and androgen deprivation therapy (ADT) was approved for the treatment of high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in Japan …
NAID 120006951704